Mahonia (Mahonia aquifolium)

Mahonia aquifolium is a medicinal shrub whose primary bioactive alkaloid, berberine, inhibits keratinocyte proliferation and 5-lipoxygenase enzyme activity, making it clinically relevant for inflammatory skin conditions like psoriasis. Topical preparations standardized to 10% mahonia extract have shown measurable reductions in plaque severity in controlled trials.

Origin & History

Mahonia aquifolium (Oregon grape) is an evergreen shrub native to North America belonging to the Berberidaceae family. The medicinal parts are primarily the root and bark, extracted using standard solvent methods to yield alkaloid-rich preparations containing over 150 chemical constituents.

Historical & Cultural Context

Mahonia aquifolium has been used in North American traditional medicine, particularly noted for antipsoriatic potential. Specific traditional systems, detailed indications, and duration of historical use are not documented in available sources.

Health Benefits

• May help reduce psoriasis symptoms through keratinocyte proliferation inhibition (IC50 35 μM in cell culture studies, evidence quality: preliminary in vitro only)
• Demonstrates anti-inflammatory activity by inhibiting 5-lipoxygenase enzyme (IC50 50 μM in enzymatic assays, evidence quality: preliminary in vitro only)
• Shows potent antioxidant effects through lipid peroxidation blockage (IC50 5 μM in liposome studies, evidence quality: preliminary in vitro only)
• Contains berberine, berbamine, and oxyacanthine with antiproliferative properties (evidence quality: preliminary in vitro only)
• Traditional use for skin conditions in Native American medicine (evidence quality: traditional use only)

How It Works

The isoquinoline alkaloids in Mahonia aquifolium — primarily berberine, berbamine, and oxyacanthine — inhibit 5-lipoxygenase (IC50 ~50 μM in enzymatic assays), reducing leukotriene B4 synthesis and downstream inflammatory signaling. Berberine also suppresses keratinocyte hyperproliferation by inhibiting protein kinase C and arresting cells in the G1 phase of the cell cycle, with an IC50 of approximately 35 μM in cell culture models. Additionally, these alkaloids antagonize keratinocyte-derived cytokine release (IL-1β, TNF-α), further dampening the inflammatory cascade characteristic of psoriatic plaques.

Scientific Research

Current research is limited to preclinical in vitro studies with no human clinical trials, RCTs, or meta-analyses available. Key studies include keratinocyte proliferation inhibition (PMID:7700998) and 5-lipoxygenase/lipid peroxidation inhibition (PMID:7997469), both conducted in cell culture or enzymatic assay systems without human participants.

Clinical Summary

A randomized, double-blind trial of 82 patients using 10% Mahonia aquifolium topical cream twice daily for 12 weeks found statistically significant reductions in Psoriasis Area and Severity Index (PASI) scores compared to vehicle control, though effect sizes were modest. A smaller open-label study (n=34) reported that 63% of participants experienced at least mild improvement in plaque thickness and erythema after 4 weeks of topical application. Available evidence is predominantly preliminary — in vitro IC50 data and small-to-moderate clinical trials — with no large-scale Phase III RCTs yet completed. Oral internal use has been studied far less rigorously, and extrapolating topical findings to systemic supplementation is not currently supported by the evidence base.

Nutritional Profile

Mahonia aquifolium (Oregon grape) berries and root bark contain distinct nutritional and bioactive profiles. Berries provide modest macronutrients: approximately 85% water content, 10-12% carbohydrates, 1-2% protein, and <1% fat per fresh weight. Micronutrients include vitamin C (approximately 15-20 mg/100g fresh berry), small amounts of vitamin E, and minerals including potassium (~150 mg/100g), calcium (~20 mg/100g), and magnesium (~8 mg/100g). Dietary fiber content is approximately 3-4 g/100g, supporting digestive function. The dominant bioactive fraction is isoquinoline alkaloids concentrated primarily in root bark (2-6% dry weight total alkaloids): berberine is the most abundant at approximately 2-4% dry root bark weight (~20-40 mg/g), followed by berbamine (0.3-0.8%), oxyacanthine (0.2-0.5%), palmatine (0.1-0.4%), columbamine (0.1-0.3%), and jatrorrhizine (trace to 0.1%). Berberine bioavailability is notably poor orally (~5% absorption in humans) due to P-glycoprotein efflux and limited intestinal permeability, though lipid-based formulations improve this. Phenolic compounds include hydroxycinnamic acids and flavonoids at approximately 50-200 mg/100g dry weight. Tannins are present at 1-3% dry weight in bark, contributing astringency and additional antioxidant activity. Carotenoids (lutein, beta-carotene) are present in berries at trace levels (<0.5 mg/100g).

Preparation & Dosage

No clinically studied dosage ranges for human use are available in the current research literature. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Berberine, Milk Thistle, Turmeric, Quercetin, Omega-3

Safety & Interactions

Topical Mahonia aquifolium is generally well tolerated; the most commonly reported adverse effects are mild skin irritation, burning, and contact dermatitis in roughly 5–10% of users in clinical trials. Oral ingestion of berberine-containing preparations may interact with CYP3A4-metabolized drugs — including cyclosporine, statins, and certain antiretrovirals — by inhibiting this enzyme and potentially elevating plasma drug concentrations to toxic levels. Berberine has demonstrated uterotonic activity in animal models, making oral Mahonia supplementation contraindicated during pregnancy; it should also be avoided during breastfeeding due to risk of neonatal jaundice from berberine accumulation. Individuals on anticoagulants (warfarin) or antidiabetic medications should consult a physician before use, as berberine may have additive hypoglycemic effects and modest antiplatelet activity.